Journal Logo



Yan, Y.1; An, G.1; Mao, X.1; Liu, J.1; Fan, H.1; Yi, S.1; Li, Z.1; Wang, T.1; Sui, W.1; Liu, W.1; Wang, Q.1; Deng, S.1; Zou, D.1; Qiu, L.1

doi: 10.1097/01.HS9.0000560648.47141.e6
Poster Session I: Myeloma and other monoclonal gammopathies - Clinical

1Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China

Back to Top | Article Outline


The importance of deep response is now well-accepted in multiple myeloma (MM). So far techniques for detection of minimal residual disease (MRD) mainly focus on identifying fewer magnitude of residual cells (<10-6) using more sensitive technologies. However, limit attention has been paid to explore the biological and genetic features of the minimal residual cells.

Back to Top | Article Outline


Interphase fluorescence in situ hybridization (iFISH) analyses in sequential samples provide a simple and reliable method to longitudinal track the dynamic changes in clonal architecture and speculate the possible evolutionary pattern. Here, we report for the first time the incidence and prognostic significance of cytogenetic abnormalities (CA) existed in the residual plasma cells (PCs) of patients achieving at least partial remission.

Back to Top | Article Outline


A cohort of 193 patients with at least one cytogenetic abnormalities (CA) at diagnosis were analyzed using data from the prospective, non-randomized clinical trial (BDH 2008/02), and iFISH analyses were performed in patient-paired diagnostic and post-therapy samples.

Back to Top | Article Outline


Persistent CA in residual tumor cells were observed for the majority of patients (63%), even detectable in 28/63 (44%) patients with MRD negativity (<10-4). The absence of CA in residual PCs was associated with prolonged survival regardless of MRD status. It was noted that MRD-positive but FISH-negative patients experienced similar survival to MRD-negative patients (m-TTP 4.5 vs. 5.1 years, P = 0.983).

According to the change of the clonal size of specific CA, patients were clustered into four groups, reflecting four patterns of clone selection under therapy pressure. 1) Pattern A were observed in 35 (18%) patients where a minor subpopulation or undetectable subclone in the pre-treatment sample became dominant after therapy. 2) Pattern B was identified in 30 (16%) patients whose fractions of PCs harboring different CA were decreased with inconsistent extent. 3) Stable cytogenetic architecture under therapy pressure were found in 57 (30%) patients as Pattern C. 4) 71 patients lost their abnormal cytogenetic clone after therapy (less than cut-off level) were classified as Pattern D. The cytogenetic dynamics of pattern A and B can be interpreted as a therapy-induced selection process with comparable inferior survival (m-TTP 1.2 vs. 1.8 years, respectivel). Patients with pattern D experienced the most favorable outcome (m-TTP 5.0 years), following those with pattern C (m-TTP 3.5 years).

Among the 65 patients with clonal selection, 24 underwent upfront auto-transplantation that experienced significantly improved survival. However, upfront transplant failed to completely reverse the inferior outcome caused by therapy-induced clonal selection. Longitudinal cytogenetic studies at relapse were available in 43 patients. The results suggested that sequential cytogenetic dynamics were observed in most patients, and the cytogenetic architecture of residual cells could to some extent predict the evolutional pattern at relapse.



Back to Top | Article Outline


The repeat cytogenetic evaluation in residual PCs could not only serves as a good complementary tool for MRD detection, but also provides a better understanding of clinical response and clonal evolution. Therapy-induced clonal selection was associated with inferior outcome regardless of the baseline cytogenetic profiles. The early identification of resistant clone may contribute to guide better tailored therapy strategies based on the feature of the residual tumor cells.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.